BioCentury
ARTICLE | Clinical News

Momenta reports equivalence data for generic Copaxone

April 18, 2015 12:53 AM UTC

Momenta Pharmaceuticals Inc. (NASDAQ:MNTA) said data demonstrate equivalence between its once-daily Glatopa glatiramer acetate and blockbuster multiple sclerosis (MS) drug Copaxone from Teva Pharmaceutical Industries Ltd. (NYSE:TEVA). On Thursday, FDA approved Glatopa, the first generic version of Copaxone.

An abstract released in advance of next week's annual meeting of the American Academy of Neurology described no differences in the structure and function of Glatopa and Copaxone and reported equivalence of physiochemical and biological properties. In a second study, Glatopa was equivalent to Copaxone as measured by its effect on changes in T cell gene expression. ...